Sign in to continue:

Saturday, March 21st, 2026

Enbridge Inc. 2026 Annual Shareholders Meeting Notice, Voting Instructions, and Access to Meeting Materials 123




Enbridge Inc. 2026 Annual Meeting: Key Details for Investors

Enbridge Inc. Announces Details of 2026 Annual Shareholders’ Meeting

Summary of Key Points

  • Annual Meeting Date and Format: The 2026 annual meeting of Enbridge Inc. shareholders will take place virtually on May 6, 2026, at 1:30 p.m. Mountain Time. Shareholders can participate via live audio webcast at this link using the password “enbridge2026” (case sensitive).
  • Notice-and-Access: As part of an environmentally friendly and cost-effective approach, Enbridge is using “notice-and-access” to deliver the 2026 Management Information Circular, the 2025 Annual Report, and other meeting materials online instead of mailing them. Materials are accessible at Enbridge’s Investment Center website or sedarplus.ca. Shareholders receive a proxy form by mail for voting.
  • Voting Items at the Meeting:

    • Election of 12 directors, as nominated in the Management Information Circular, to serve until the next annual meeting.
    • Appointment of PricewaterhouseCoopers LLP as the independent auditor, with authorization for directors to set their remuneration.
    • Advisory (non-binding) vote on Enbridge’s executive compensation approach.
    • Amendment, reconfirmation, and approval of Enbridge’s shareholder rights plan.
  • How to Vote: Shareholders cannot vote by returning the notice alone. Voting can be done via:

    • Internet: investorvote.com
    • Telephone: 1-866-732-VOTE (8683)
    • Mail: By returning the enclosed proxy form in the provided pre-paid envelope.

    Voting instructions must be received by 1:30 p.m. MT on May 4, 2026.

  • Requesting Paper Copies: Shareholders may request free paper copies of the Management Information Circular and 2025 Annual Report by using the control number from their proxy form. To ensure receipt before the meeting, requests must be made no later than April 28, 2026. Requests can be made toll-free at 1-866-962-0498 (North America) or 1-514-982-8716 (outside North America).
  • Investor Relations Contact: For post-meeting support or further inquiries, contact Enbridge Investor Relations at 1-800-481-2804 (North America) or [email protected].

Potential Share Price Implications & Noteworthy Considerations

  • Director Elections: The election of directors is a routine annual event; however, any changes in director nominees or board composition may be scrutinized by investors for signals of strategic shifts or governance changes.
  • Auditor Appointment: The re-appointment of PricewaterhouseCoopers LLP as auditor is standard, but any shareholder opposition or change could impact investor confidence.
  • Executive Compensation: The advisory vote on executive compensation provides shareholders with a voice in pay practices. A significant “no” vote could signal investor dissatisfaction and impact share perception.
  • Shareholder Rights Plan: The amendment, reconfirmation, and approval of the shareholder rights plan is notable as it may relate to takeover defenses or changes in shareholder protections. Investors should review the details in the Management Information Circular for implications on potential mergers, acquisitions, or hostile bids.
  • Notice-and-Access Process: The move to notice-and-access is increasingly common, reducing company costs and environmental impact, but shareholders must ensure they access the necessary documents online or request paper copies to stay informed and exercise their voting rights.

Important Action Items for Shareholders

  • Review the Management Information Circular and 2025 Annual Report before voting.
  • Vote using one of the approved methods by the stated deadline to ensure your shares are represented.
  • Request paper copies of materials if needed before April 28, 2026.
  • Retain your proxy form, as no additional forms will be sent.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult their financial advisors before making investment decisions. The information provided is based on company disclosures as of March 20, 2026, and may be subject to change.




View ENBRIDGE INC Historical chart here



Milestone Pharmaceuticals Reports 2025 Financial Results and Launch of FDA-Approved CARDAMYST Nasal Spray for PSVT

Milestone Pharmaceuticals Reports Q4 and FY 2025 Results: CA...

GREIF, INC. 8-K SEC Filing Summary: Company Information, Stock Details, and Filing Data (Feb. 25, 2026)

Greif, Inc. 2026 Annual Meeting: Key Shareholder Votes and I...

ANI Pharmaceuticals Presents Updated Investor Presentation at Raymond James 2026 Conference

ANI Pharmaceuticals Projects Over \$1 Billion in 2026 Revenu...

   Ad